Impact of baseline alterations in HER2-pathway oncogenic drivers on response to anti-HER2 therapy in patients (pts) with HER2-amplified advanced colorectal cancer (aCRC).
Celine Hoyek(Mayo Clinic Hospital), Tanios Bekaii‐Saab(WinnMed), Oluseyi Abidoye(Mayo Clinic), Yoshiaki Nakamura(National Cancer Center Hospital East), Taro Shibuki(National Cancer Center Hospital East), Mitesh J. Borad(Jacksonville College), Masafumi Ikeda(National Cancer Center Hospital East), Binbin Zheng-Lin(WinnMed), Cody Eslinger(WinnMed), Mohamad Bassam Sonbol(WinnMed), Takayuki Yoshino(University of Tsukuba), Daniel H. Ahn(Mayo Clinic Hospital), Ryne C. Ramaker(Duke Medical Center), Angelo Pirozzi(Humanitas University), Christina Wu(WinnMed), John H. Strickler(Duke Medical Center)
Cited by 0
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k